Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Non Small Cell Lung Cancer For in the study subjects should fulfill the following 1. Provision of written informed consent to treatment and companion translational studies prior to any study specific procedures 2. Patients must be > 18 years of age. 3. Affiliation to an health insurance 4. Histological diagnosis of NSCLC 5. Advanced or metastatic disease (stage IIIB/IV) 6. Access to the original tumor biopsy or planning of a fresh tumor biopsy before start the platinium based chemotherapy 7. Chemonaive for NSCLC or patient having received adjuvant chemotherapy at least 2 years before trial enrolment or patient currently receiving his/her first platinum-based chemotherapy for advanced NSCLC (first line or second line only if the first line was an anti-PD-1 or anti-PD-L1 agent monotherapy) 8. No other cancer in the previous 3 years, except cervical cancer or cutaneous cancer 9. Absence of EGFR-sensitising mutation or ALK translocation 10. ECOG Performance Status of 0-1 11. Fit to receive 6 cycles or currently receiving of platinum-based induction chemotherapy 12. At the start of the platinium based induction chemotherapy measurable lesions by v1.1 i.e. at least one lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10mm in the longest diameter (except lymph nodes that must have short axis ≥ 15mm) with computed tomography (CT), magnetic resonance imaging (MRI) or clinical examination and which is suitable for accurate repeated measurements. 13 is only for patients registered before starting the platinum-based induction chemotherapy: 13. Patients must have normal organ and bone marrow function measured within 14 days prior to administration of the platinum based treatment Haemoglobin ≥ 10.0 g/dL Absolute neutrophil count (ANC) ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case it must be ≤ 5x ULN Creatinine clearance > 60mL/min as calculated by Cockroft-Gault formula for cisplatin administration; creatinine clearance >/= 51mL/min by Cockroft-Gault formula for carboplatin administration 14. Evidence of non-childbearing status for women of childbearing potential: negative serum pregnancy test within 14 days of study treatment. Postmenopausal is defined as Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments LH and FSH levels in the post-menopausal range for women under 50 Radiation-induced oophorectomy with last menses >1 year ago